Effect of cardiac resynchronization therapy and implantable cardioverter defibrillator on quality of life in patients with heart failure: a meta-analysis. Cardiac resynchronisation therapy TREATS Heart failure
CONCLUSIONS: The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting, a defined and scalable practice-specific performance improvement intervention, was associated with substantial improvements in the use of guideline-recommended therapies in eligible patients with HF in outpatient cardiology practices. Intervention regimes TREATS Heart failure
Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). ivabradine TREATS Heart failure
AIMS: The GISSI-HF trial showed that n-3 polyunsaturated fatty acids (PUFA), but not rosuvastatin, reduce morbidity and mortality in patients with symptomatic heart failure (HF) of any cause. rosuvastatin TREATS Heart failure
Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Metformin TREATS Heart failure
A trial comparing all 3 drugs would be required to confirm torsemide as the primary loop diuretic in patients with HF, but based upon limited current evidence, we recommend torsemide over furosemide. Loop Diuretics TREATS Heart failure
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). coenzyme Q10 TREATS Heart failure
Evaluating the potential benefits of metformin in patients with cardiovascular disease and heart failure. Metformin TREATS Heart failure
Physical exercise has been shown to be safe for people with heart failure. Exercise TREATS Heart failure
Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. Injection procedure TREATS Heart failure
METHODS AND RESULTS: This substudy of the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) trial measured plasma levels of procollagen type I amino-terminal peptide, procollagen type III amino-terminal peptide, and osteopontin in 334 patients with HFPEF. irbesartan TREATS Heart failure
Overall, statins did not affect all-cause or cardiovascular mortality but did significantly decrease hospitalization for worsening HF during follow-up (odds ratio [OR] 0.67, p = 0.008). Hospitalization TREATS Heart failure
Angiotensin-converting enzyme inhibitors (ACEIs) are the foremost therapeutic option in the management of CHF. Angiotensin-Converting Enzyme Inhibitors TREATS Congestive heart failure
Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Bisoprolol TREATS Heart failure
OBJECTIVES: The aim of this study was to confirm the generalizability of the conclusions of the STICH (Surgical Treatment for Ischemic Heart Failure) trial. Operative Surgical Procedures TREATS Heart failure
Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial. Aspirin TREATS Heart failure
Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. aliskiren TREATS Heart failure
Palliative care and hospice in advanced heart failure. Palliative Care TREATS Heart failure
Quality of life questionnaires (Ladder of Life, RAND36, and Minnesota Living with Heart Failure Questionnaire) and BNP levels were assessed at discharge after a hospital admission for HF. Hospital admission TREATS Heart failure
Our review data suggest that physical therapies employing >= 5 sessions per week are most likely to reduce serum levels of TNF-alpha in HF patients. Physical therapy TREATS Heart failure
Patients received either prednisone 1 mg kg(-1) day(-1) for 4 weeks followed by 0.33 mg kg(-1) day(-1) for 5 months and azathioprine 2 mg kg(-1) day(-1) for 6 months (43 patients, Group 1) or placebo (42 patients, Group 2) in addition to conventional therapy for heart failure. Placebos TREATS Heart failure
Spironolactone was well tolerated when combined with conventional heart failure treatment. Spironolactone TREATS Heart failure
A lower pulse pressure did not predict hospitalisation for worsening heart failure. Hospitalization TREATS Heart failure
CONCLUSIONS: This analysis, limited to trial level data from different therapeutic eras, suggests that drug- or device-induced effects on peak VO(2), 6MW, and natriuretic peptides found in short-term trials do not predict the corresponding average long-term therapeutic effects on mortality for patients with HF and left ventricular dysfunction. Natriuretic Peptides TREATS Heart failure
The role of CRT is less well established in AF patients with coexistent heart failure. Cardiac resynchronisation therapy TREATS Heart failure
Mortality of newly diagnosed heart failure treated with amiodarone A propensity-matched study. Amiodarone TREATS Heart failure
We analyzed the effects of trimetazidine on QTc interval in patients with ischemic heart failure. Trimetazidine TREATS Heart failure
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. carvedilol TREATS Heart failure
CONCLUSIONS: Vitamin D supplementation did not improve functional capacity or quality of life in older patients with heart failure with vitamin D insufficiency. Vitamin supplementation TREATS Heart failure
Tolvaptan was administered at 7.5 or 15 mg, in combination with furosemide, for 7 days in Japanese heart failure (HF) patients with volume overload that had not resolved despite receiving furosemide. Furosemide TREATS Heart failure
Warfarin and aspirin in patients with heart failure and sinus rhythm. Aspirin TREATS Heart failure
[Is the low-sodium diet actually indicated for all patients with stable heart failure?]. Diet, Sodium-Restricted TREATS Heart failure
Comparison of CRT and CRT-D in heart failure: systematic review of controlled trials. Cardiac resynchronisation therapy TREATS Heart failure
PATIENTS: The original trial enrolled 314 patients with heart failure who were aged 50 years or older and were taking at least one cardiovascular drug for heart failure; Cardiovascular Agents TREATS Heart failure
Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Treatment Protocols TREATS Heart failure
The authors sought to determine by systematic review whether physical therapy reduces serum levels of pro-inflammatory cytokines in HF patients. Physical therapy TREATS Heart failure
Remote patient monitoring was associated with a significantly lower number of hospitalizations for HF [incidence rate ratio (IRR): 0.77, 95% CI 0.65-0.91, P < 0.001] and for any cause (IRR: 0.87, 95% CI: 0.79-0.96, P = 0.003), while LOS was not different. Hospitalization TREATS Heart failure
A 10% increase in the number of eligible patients receiving ACE inhibitors (n = 191) could result in at least 18 fewer deaths (95% CI 9.8 to 27.1) and 32 fewer hospitalisations (95% CI 24.9 to 40.7) for heart failure every year. Hospitalization TREATS Heart failure
Effects of cAMP and beta-adrenergic receptor antagonists on the function of peripheral T helper lymphocytes in patients with heart failure. Adrenergic Antagonists TREATS Heart failure
Crossover from assigned therapy, therefore, diminished the impact of CABG on survival in STICH when analyzed by intention to treat. Coronary Artery Bypass Surgery TREATS Heart failure
Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. Diuretics TREATS Heart failure
Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). carvedilol TREATS Heart failure
CONCLUSION: Ivabradine improves outcomes in heart failure patients with heart rate >/=70 b.p.m. receiving multiple neurohormonal modulation treatments (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, beta-blocker, and MRA). ivabradine TREATS Heart failure
Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial. metoprolol succinate TREATS Heart failure
Therefore, sleep studies and LVEFs of HF patients with CSA from the control arm of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure (CANPAP) trial were examined to determine whether some converted to mainly OSA and, if so, whether this was associated with an increase in LVEF. Continuous Positive Airway Pressure TREATS Heart failure
Is addition of angiotensin receptor blockade superior to increasing ACE inhibitor dose in patients with heart failure? Angiotensin-Converting Enzyme Inhibitors TREATS Heart failure
Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. Losartan TREATS Heart failure
After adjustment, nonpersistence was associated with the composite end point of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure (hazard ratio 1.24, 99% CI 1.09-1.40, P < .0001), cardiovascular death alone (1.87, 1.60-2.19, P < .0001), and heart failure hospitalization alone (1.32, 1.04-1.67, P = .0023). Hospitalization TREATS Heart failure
OBJECTIVE: To review the literature evaluating the clinical effects of combination therapy with a beta-blocker and milrinone in patients with severe heart failure (HF). Adrenergic beta-Antagonists TREATS Heart failure
Inspiratory muscle training in heart disease and heart failure: a review of the literature with a focus on method of training and outcomes. Inspiratory muscle training TREATS Heart failure
METHODS AND RESULTS: Baseline characteristics and cardiovascular outcomes were assessed in the 4109 patients (mean age, 72 years; mean follow-up, 49.5 months) in the Irbesartan in HF with Preserved Ejection Fraction (I-PRESERVE) trial. irbesartan TREATS Heart failure
